sparsentan

Term ID

CHEBI:229526

Synonyms

2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[biphenyl]-2-sulfonamide
esparsentan
Filspari
PS 433540
PS-433540
PS433540
RE-021
sparsentan
sparsentanum

Definition

A biphenyl that is 1,1'-biphenyl substituted by (4,5-dimethyl-1,2-oxazol-3-yl)aminosulfonyl, ethoxymethyl, and (2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl groups at positions 2, 2' and 4', respectively. It is a dual antagonist of endothelin and angiotensin II receptors approved for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.

References

drugbank:DB12548
kegg.drug:D11776
pubmed:29142983
pubmed:30361325
pubmed:32274453
pubmed:35052766
pubmed:36852566
pubmed:37015244
pubmed:37022667
pubmed:37081176
pubmed:37140613
pubmed:37180506
pubmed:37221817
pubmed:37256677
pubmed:37278973
pubmed:37466432
pubmed:37499685
pubmed:37706310
pubmed:37850006
pubmed:37903508
pubmed:37921461
pubmed:37921485
pubmed:37931634
pubmed:38012264
pubmed:38041499
pubmed:38149041
pubmed:38271614
pubmed:38362830
pubmed:38507767
pubmed:38507768
pubmed:38507769
pubmed:38511222
wikipedia.en:Sparsentan

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from sparsentan

Phenotype where environments contain sparsentan

Phenotype modified by environments containing sparsentan

Phenotype affecting sparsentan

Human Disease Model